rvsv-sudv
Vaccineexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 31, 2023 (NCT05909358)
Timeline
2020s
- Jan 1, 2023
Earliest Phase 1 Sponsor(trial)
Indications
Studied for
Mechanism of action
- EbolavirusImmunity, active
Ebolavirus immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05909358 | Phase 1/Phase 2 (Phase 2) | Jul 31, 2023 | Epicentre, Government of Uganda, Makerere University, Medical Research Council-UVRI Uganda Research Unit on AIDS |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Epicentre | For profit | 1 | 0 | 1 | 2023 |
| Government of Uganda | Government | 1 | 0 | 1 | 2023 |
| Makerere University | Academic/Hospital | 1 | 1 | 1 | 2023 |
| Medical Research Council-UVRI Uganda Research Unit on AIDS | Academic/Hospital | 1 | 0 | 1 | 2023 |
4 organizations
Page 1 / 1